Gamida Cell Announces orphan drug designation for NiCord®
Release Date: 08-Apr-2017
European Medicine Agency (EMA) has announced orphan drug status for NiCordandreg; developed by Gamida cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, to treat haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation (BMT). Presently, the orphan drug is being evaluated internationally as a graft for bone marrow transplantation for patients with blood cancer who do not have a rapidly available fully matched donor.
The EMA orphan drug designation is a status assigned to a medicine intended for use against a rare condition (prevalence of the condition in the European Union must not be more than 5 in 10,000) and allows a pharmaceutical company to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life threatening or a chronically debilitating rare disease.
“Global Orphan Drug Clinical Pipeline Insight” reports by kuick research gives comprehensive insight on various clinical and non-clinical aspects associated with ongoing clinical trials of 808 orphan designated drugs across the globe. The in-depth clinical insight presented in the report helps the reader to analyze and identify the various stakeholders involved in the clinical development and commercialization of orphan designated drugs in the global market. Currently there are more than 300 orphan designated drugs commercially available in the global market and around 800 drugs in clinical development phase.
